Brandon Greer Busbee MD
Retinal Disease
Retina surgery and medicine / Partner Tenneessee Retina
Join to View Full Profile
345 23rd Ave NSuite 350Nashville, TN 37203
Phone+1 615-983-6000
Fax+1 615-983-6010
Dr. Busbee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalResidency, Ophthalmology, 1999 - 2002
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 1998
Certifications & Licensure
TN State Medical License 2004 - 2026
MA State Medical License 2002 - 2004
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Evaluation of Dosing Interval of Higher Doses of Ranibizumab Start of enrollment: 2007 Sep 01
- On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) Start of enrollment: 2012 Aug 01
- Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Start of enrollment: 2013 Jun 01
Publications & Presentations
PubMed
- 24 citationsSafety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phas...Arshad M Khanani, David S Boyer, Charles C Wykoff, Carl D Regillo, Brandon G Busbee
Eclinicalmedicine. 2024-01-01 - 20 citationsCost-utility analysis of cataract surgery in the United States for the year 2018.Gary C. Brown, Melissa M. Brown, Brandon G. Busbee
Journal of Cataract and Refractive Surgery. 2019-07-01 - 249 citationsEfficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.Frank G. Holz, Srinivas R. Sadda, Brandon G. Busbee, Emily Y. Chew, Paul Mitchell
JAMA Ophthalmology. 2018-06-01
Journal Articles
- Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular DegenerationSrinivas R Sadda, Brandon Busbee, Emily Y Chew, Neil M Bressler, JAMA
Press Mentions
Adverum Biotechnologies Presents Long-Term Data Through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-Experienced Wet AMD Patients at ARVO 2021May 1st, 2021
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
